Efficacy and safety of chemotherapy combined with interstitial 125 I seed implantation brachytherapy in advanced non-small cell lung cancer
-
摘要: 目的 观察放射性粒子125 I植入联合化疗治疗晚期非小细胞肺癌( NSCLC)的临床疗效和安全性.方法 68例ⅢB～Ⅳ期NSCLC患者分为粒子植入联合化疗组(实验组)32例和化疗组(对照组)36例,化疗方案为吉西他滨联合顺铂,观察有效率和无进展生存期以及毒副作用,有效率和毒副反应率采用x2检验,Kaplan-Meier生存曲线分析无进展生存时间,无进展生存率比较采用Log-rank检验.结果 试验组和对照组的总体反应率分别为75％和44.44％.2组间有显著的统计学差异(P＜0.05),中位无进展生存期分别为6.5个月和4.5个月,统计学差异显著(P＜0.05),实验组显著长于对照组.所有的副作用/并发症可控,实验组有较高的血痰和胸痛发生率,两组在气胸、发热、骨髓抑制方而无差异,未观察到粒子游走.结论 放射性粒子125 I植入联合化疗治疗晚期非小细胞肺癌有较好的临床疗效和可以控制的毒副作用,是晚期非小细胞肺癌安全、有效的治疗手段.
-
-
Borchers H, Krischmer-Hermanns R, Brehmer B. Permanent 125I-seed brachytherapy or radical prcstatectomy:a prospective comparison considering oncological and quality of life results [J]. British Journal of Urology International, 2004(6):805.doi: 10.1111/j.1464-410X.2004.05037.x. Lee W, Daly B D, DiPetrillo T A. Limited resection for non-small cell lung cancer:observed local control with implantation of 125I brachytherapy seeds [J]. Annals of Thoracic Surgery, 2003(1):237. Colonias A, Betler J, Trombetta M. Mature follow-up for high-risk stage Ⅰ non-small-cell lung carcinoma treated with sublobar resection and intraoperative iodine-125brachytherapy [J]. International Journal of Radiation Oncology ? Biology ? Physics, 2011(1):105. 韦国桢, 殷小伟, 薛跃君. CT引导下组织间植入125 I粒子治疗肺癌的临床应用 [J]. 中国微创外科杂志, 2008(3):243.doi: 10.3969/j.issn.1009-6604.2008.03.020. 付改发, 雷光焰, 宋养荣. 125I粒子植入联合化 放疗治疗局部复发性晚期肺癌 [J]. 中国微创外科杂志, 2008(7):596.doi: 10.3969/j.issn.1009-6604.2008.07.008. Yang S F, Fan X W, Zhang G Q. Efficacy and safety of chemotherapy combined with interstitial 125I seed implantation brachytherapy in unresectable stage Ⅲ a/Ⅲ b non-small cell lung cancer [J]. Zhonghua Zhongliu Zazhi, 2010(8):626.doi: 10.3760/cma.j.issn.0253-3766.2010.08.016. 余红波, 崔亚利, 郭雨栋. 125I粒子与放疗分别联合化疗治疗ⅢB期NSCLC的比较 [J]. 实用肿瘤学杂志, 2008(1):23.doi: 10.3969/j.issn.1002-3070.2008.01.008. 张旭, 岳世昌, 赵翌. 手术加125 I粒子植入治疗肺癌的初步评价 [J]. 实用医学杂志, 2005(4):375.doi: 10.3969/j.issn.1006-5725.2005.04.017. Furuse K, Fukuoka M, Kawahara M. Phase Ⅲ study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage Ⅲ non-small-cell lung cancer [J]. Journal of Clinical Oncology, 1999(9):2692.
计量
- 文章访问数: 168
- HTML全文浏览量: 24
- PDF下载量: 10
下载:
苏公网安备 32100302010246号
